> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Fast Track for Volastra Ovarian Cancer Drug
- URL: https://www.fdaweb.com/fda-fast-track-for-volastra-ovarian-cancer-drug/
- Published: 2024-10-02T12:00:00.000Z
- Updated: 2026-09-14T14:42:58.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157903

FDA has given fast-track designation to Volastra Therapeutics’ VLS-1488, an internally discovered KIF18A inhibitor to treat patients with platinum-resistant high-grade serous ovarian cancer. A company [statement](https://www.businesswire.com/news/home/20241002653121/en/Volastra-Therapeutics-Granted-FDA-Fast-Track-Designation-for-Novel-KIF18A-Inhibitor-in-Ovarian-Cancer?ref=fdaweb.com) says a Phase 1/2 trial is evaluating the safety, tolerability, and preliminary efficacy in patients with advanced tumors, including high-grade serous ovarian cancer.